Process Engineer Trainee

Pharma contract firm Hovione opens East Windsor facility, doubling U.S. spray-drying capability. ROI-NJ Staff(East Windsor) September 17, 2026 Marco Gil, co-CEO Hovione; Janice Mironov, Mayor East Windsor, NJ; Debbie Hart, President BioNJ; Antonio Almeida, co-CEO Hovione; David Basile, VP TechOps Americas Hovione. - Hovione Hovione, a pharmaceutical contract development and manufacturing organization (CDMO), opened 89 Twin Rivers, a 31,000-square-foot facility at its East Windsor campus on Sept. 15. The new facility doubles the company's U.S. spray drying capacity. The facility adds two GMP-ready, commercial-scale PSD-3 spray dryers, expanding Hovione's manufacturing capacity central to its integrated development and manufacturing platform spanning drug substance, spray drying and drug product manufacturing. Operating under the campus's FDA registration and harmonized quality system, the expanded platform enables customers to reduce technology transfer, facilitate scale-up and provide greater manufacturing continuity. About 70% of small-molecule drug candidates exhibit poor aqueous solubility, limiting bioavailability and slowing development. Hovione addresses this formulation challenge by turning poorly soluble drug ingredients into more bioavailable forms using amorphous solid dispersions through its spray drying platform. The company also draws on more than 25 years of specialized spray-drying manufacturing expertise, including formulation science, predictive and model-based development tools, scale-up expertise, and drug product manufacturing, to help customers address this challenge. The opening of the 89 Twin Rivers facility completes Hovione's current $100 million U.S. investment cycle and represents the first major milestone in the next phase of evolution of its integrated East Windsor campus. Over the coming decade, Hovione plans to continue growing its U.S. operations, further strengthening the site as a next-generation pharmaceutical development and manufacturing hub. The new facility will employ about 80 people. "Opening 89 Twin Rivers...marks the next chapter in Hovione's legacy of more than two decades in the U.S.," said Marco Gil and Antonio Almeida, co-chief executive officers of Hovione. "This investment enables ROI-NJ to meet growing demand while further reinforcing its global leadership in pharmaceutical spray drying. "Equally important, this technology sits within an integrated offering that extends from drug substance through drug product, giving customers a more direct and resilient path from early development to commercialization. This is how we help them address poor solubility, one of the industry's most persistent development challenges, and bring complex medicines to patients faster." The East Windsor campus will continue to expand over the next five to 10 years, with plans to develop about 15 acres of adjacent property into a 125,000-square-foot manufacturing facility that supports additional laboratories, commercial-scale spray drying, and drug product manufacturing. Hovione partners with 19 of the world's 20 largest pharmaceutical companies. It is involved in up to 10% of medicines approved annually by the Food and Drug Administration.

Hovione pharmaceutical company opens 31K sq. Ft. Facility in East Windsor, adding area jobs. Hovione opens a new East Windsor campus, doubling U.S. spray-drying capacity and adding 80 jobs as part of a $100M expansion. Marco Gil, co-CEO, Hovione; Janice Mironov, Mayor, East Windsor, NJ; Debbie Hart, President, BioNJ; Antonio Almeida, co-CEO, Hovione; David Basile, VP of TechOps - Americas, Hovione Photo Credit: Brandwidth Solutions Published September 17, 2026 at 7:00 AM Last updated September 17, 2026 at 12:49 PM EAST WINDSOR, N.J. - The globally-integrated pharmaceutical company, Hovione, officially expanded its footprint in East Windsor Township with a ribbon cutting ceremony held on Tuesday at their new 31,000-square-foot campus that will double capacity and add local jobs. With the opening of the new Hovione site, 89 Twin Rivers, the Contract Development and Manufacturing Organization (CDMO) will double its U.S. spray drying capacity and further reinforces Hovione ́s global leadership in this technology platform. The facility opening completes Hovione's current $100 million U.S. investment cycle and represents the first major milestone in the next phase of evolution of its integrated East Windsor, N.J., campus. The new Hovione facility will add 80 jobs to the community. Get local news you can trust in your inbox. Marco Gil and Antonio Almeida, Co-Chief Executive Officers of Hovione, said that the site opening is more than a capacity expansion. "It marks the next chapter in Hovione's legacy of more than two decades in the U.S.," they said. "This investment enables us to meet growing demand while further reinforcing our global leadership in pharmaceutical spray drying. Equally important, this technology sits within an integrated offering that extends from drug substance through drug product, giving customers a more direct and resilient path from early development to commercial." "This is how we help them address poor solubility, one of the industry's most persistent development challenges, and bring complex medicines to patients faster." The company says that in the next decade, it is Hovione's vision is to continue growing its U.S. operations, further strengthening the site as a next-generation pharmaceutical development and manufacturing hub. Additionally, the company will continue to expand at its East Windsor campus in the next five to ten years with plans to develop approximately 15 acres of adjacent property into a 125,000-square-foot manufacturing facility supporting additional laboratories, commercial-scale spray drying and oral drug product manufacturing. East Windsor Township Mayor Janice Mironov said that the ribbon cutting was "an exciting milestone in the continuing growth and success of our local pharmaceutical life sciences company Hovione."' "East Windsor is proud to be the North American hub for Hovione's innovative work, substantial financial investment and their goal of a fully integrated campus right here, bringing materials to finished product. We look forward to a continuing beneficial partnership as they continue their successful journey," added Mironov. Hovione's 89 Twin Rivers facility adds two GMP-ready, commercial-scale PSD-3 spray dryers. The expansion of the company's manufacturing capacity is central to its integrated development and manufacturing platform spanning drug substance, spray drying and oral drug product manufacturing, they say. The 89 Twin Rivers center will operate under the campus's existing FDA registration and harmonized quality system. The expanded platform enables customers to reduce technology transfer, facilitate scale-up and provide greater manufacturing continuity. "89 Twin Rivers is a major step forward for Hovione's U.S. operations and a clear expression of our long-term commitment to East Windsor and New Jersey," said David Basile, Vice President of Technical Operations, Americas, at Hovione. "Our growth has been built on sustained investment in scientific expertise, technological innovation, advanced manufacturing capabilities, and talented people. As we look to the future, we will continue to strengthen this site as an innovation hub for pharmaceutical development and manufacturing, contributing to the competitiveness of New Jersey's life sciences ecosystem and to a stronger U.S. manufacturing base." The company further noted that the expansion of the East Windsor site is part of Hovione's international strategy "to build a network of autonomous yet harmonized development and manufacturing sites across North America, Europe and Asia." Hovione partners with 19 of the world's 20 largest pharmaceutical companies, and it is involved in up to ten percent of medicines approved annually by the U.S. Food and Drug Administration. For more information about Hovione, please visit www.hovione.com. Have a story to tell? Looking for a Marketing or Community Outreach Plan? Email Editors Elizabeth Meyers and Kristin Antonello and tell them about it. Consider the DIY platform for Community Events, Milestones, and Press Releases by Clicking SUBMIT CONTENT! Get More TAPinto Local News on Google

Hovione opens New Jersey facility, doubling U.S. Spray drying capacity. September 16, 2026 Marco Gil, co-CEO Hovione; Janice Mironov, Mayor East Windsor, NJ; Debbie Hart, President BioNJ; Antonio Almeida, co-CEO Hovione; David Basile, VP TechOps Americas Hovione Hovione has opened a new 31,000-square-foot pharmaceutical manufacturing facility at its East Windsor, New Jersey, campus, doubling the contract development and manufacturing organization's U.S. spray drying capacity and completing a $100 million investment cycle in the state. The facility, known as 89 Twin Rivers, adds two GMP-ready, commercial-scale PSD-3 spray dryers to Hovione's U.S. operations. The expansion strengthens the company's ability to move pharmaceutical programs from formulation screening through scale-up and commercial manufacturing of spray-dried amorphous solid dispersions within a single site and quality system. The project also adds approximately 80 jobs and represents the first major milestone in Hovione's longer-term plan to develop East Windsor into a larger pharmaceutical development and manufacturing hub. Spray drying has become an important manufacturing technology for drug developers confronting poor aqueous solubility, which can limit how effectively an active pharmaceutical ingredient is absorbed. Hovione estimates that approximately 70% of small-molecule drug candidates face this problem. The company uses spray drying to produce amorphous solid dispersions that can improve the bioavailability of poorly soluble drug ingredients. Hovione has more than 25 years of experience with the technology, combining formulation science, predictive and model-based development, manufacturing scale-up and finished drug product capabilities. The new capacity sits within a broader integrated platform spanning drug substance, particle engineering and drug product manufacturing. Because 89 Twin Rivers operates under the East Windsor campus' existing FDA registration and harmonized quality system, Hovione said customers can reduce technology transfers as programs advance from development into commercial production. That continuity is increasingly relevant to pharmaceutical companies looking to shorten development timelines and reduce manufacturing risk for complex products. Rather than transferring a formulation among separate development and production sites, Hovione is building capacity to support multiple stages of a program within a common operating environment. "Opening 89 Twin Rivers is more than a capacity expansion," co-CEOs Marco Gil and Antonio Almeida said. "It marks the next chapter in Hovione's legacy of more than two decades in the U.S." They said the investment is intended to meet growing demand for pharmaceutical spray drying while providing customers with a more direct pathway from drug substance through finished drug product. Hovione is already planning another significant expansion in East Windsor. Over the next five to 10 years, the company intends to develop roughly 15 acres of adjacent property with a 125,000-square-foot manufacturing facility. Plans for that site include additional laboratories, commercial-scale spray drying and drug product manufacturing. Hovione also plans to offer customers the ability to co-invest in the expansion in exchange for priority access to its technology platforms, engineering capabilities and accelerated capital deployment for their programs. The strategy positions East Windsor as a larger component of Hovione's international manufacturing network at a time when pharmaceutical companies are placing greater emphasis on regional production capacity and supply-chain resilience. Hovione is pursuing a network of autonomous but harmonized development and manufacturing operations across North America, Europe and Asia. Recent investments in Portugal and Ireland complement the New Jersey expansion and are intended to support regionalized supply and dual-site manufacturing using consistent technologies and quality systems. "89 Twin Rivers is a major step forward for Hovione's U.S. operations and a clear expression of our long-term commitment to East Windsor and New Jersey," said David Basile, vice president of technical operations, Americas. East Windsor Mayor Janice S. Mironov and BioNJ President Debbie Hart joined Hovione executives for a ribbon-cutting ceremony on September 15. Hovione currently works with 19 of the world's 20 largest pharmaceutical companies and says it is involved in as many as 10% of medicines approved annually by the U.S. Food and Drug Administration. The company operates FDA-inspected sites in the U.S., Portugal, Ireland and China, with a fifth site expected to be commissioned in 2027. The East Windsor investment expands Hovione's domestic manufacturing base while reinforcing its strategy of combining specialized formulation technology with development and commercial-scale production, an increasingly important model as drugmakers seek fewer handoffs and more resilient supply options for complex medicines.